Table 2.
Response to induction treatment. Patients who achieved CR/CRi from 1, 2, or 3 cycles of treatment induction were defined as responders. Abbreviations: WBC, white blood cell; cytogenetic risk based on MRC classification.
| Variable | Responders (n = 1901) | NO Responders (n = 996) | Significance | ||
|---|---|---|---|---|---|
| n cases | % of responders | n cases | % of responders | ||
| Sexo | |||||
| Female | 928 | 48.82 | 425 | 42.67 | p = 0.002 |
| Male | 973 | 51.18 | 571 | 57.33 | |
| Edad | |||||
| Mean (SD) | 52.49 (13.98) | 55.68 (14.36) | p < 0.001 | ||
| WBC count (×1000/mL) | |||||
| Mean (SD) | 35.82 (57.07) | 42.89 (63.01) | p = 0.004 | ||
| Cytogenetic Risk | |||||
| Low Risk | 208 | 12.21 | 30 | 3.48 | p < 0.001 |
| Intermediate Risk | 1226 | 71.95 | 522 | 60.56 | |
| High Risk | 270 | 15.85 | 310 | 35.96 | |
| NPM1 mutation | |||||
| Presence | 634 | 36.88 | 192 | 21.38 | p < 0.001 |
| Absence | 1085 | 63.12 | 706 | 78.62 | |
| FLT3 ITD mutation | |||||
| Presence | 368 | 19.33 | 211 | 21.16 | p = NS |
| Absence | 1536 | 80.67 | 786 | 78.84 | |
| FLT3 ITD ratio levels | |||||
| No mutation | 1539 | 85.26 | 785 | 83.69 | p = 0.057 |
| <0.25 | 49 | 2.71 | 26 | 2.77 | |
| 0.25-0.50 | 61 | 3.38 | 21 | 2.24 | |
| 0.501-0.80 | 57 | 3.16 | 47 | 5.01 | |
| >0.80 | 99 | 5.48 | 59 | 6.29 | |
| FLT3 ITD ratio > 0.5 | |||||
| Presence | 164 | 9.09 | 109 | 11.62 | p = 0.035 |
| Absence | 1641 | 90.91 | 829 | 88.38 | |
| FLT3 ITD ratio > 0.8 | |||||
| Presence | 99 | 5.48 | 59 | 6.29 | p = NS |
| Absence | 1706 | 94.52 | 879 | 93.71 | |